Objectives: To assess the in vitro susceptibility of Francisella tularensis subsp. holarctica biovar II strains to 24 antimicrobial agents.
Introduction
Tularaemia is a zoonotic infection caused by Francisella tularensis with a holarctic distribution and diverse clinical manifestations. 1 Only two subspecies of F. tularensis cause the vast majority of clinical tularaemia in mammals: the highly virulent subsp. tularensis (type A), which is restricted almost exclusively to North America, and subsp. holarctica (type B), which is found in Eurasia as well as in North America. Three biovars of type B have been described: biovar I (erythromycin susceptible), biovar II (erythromycin resistant), and biovar japonica. 1, 2 The clinical picture and severity of the disease in humans vary depending on the portal of entry, the virulence of the particular organism, and the immune status of the host. Clinical presentations include the six classic forms of tularaemia: ulceroglandular, glandular, oculoglandular, oropharyngeal, respiratory and typhoidal. 2, 3 Since infections with either subsp. tularensis or subsp. holarctica take a protracted course, antibiotic treatment of tularaemia is necessary. 1, 2, 4, 5 In mammals, F. tularensis invades, survives and replicates in variety of cell types including phagocytic (mainly macrophages) and non-phagocytic cells of various species. The pathogenesis of F. tularensis depends on the ability of the bacterium to survive and replicate within host cells. 1 -3 Prevention of relapses and serious sequelae may be accomplished through use of antimicrobials that have the ability to penetrate into intracellular compartments and retain efficacy even in an acidic milieu. 1, 4 We aimed to assess the susceptibility pattern of recently isolated F. tularensis subsp. holarctica strains in Yozgat, Central Anatolia, Turkey, and to analyse potential alternative therapeutic options for the treatment of infections caused by F. tularensis subsp. holarctica strains.
Materials and methods

Outbreak area
F. tularensis strains were recovered during an outbreak in the province of Yozgat between November 2009 and June 2010. Yozgat, where no human tularaemia cases had been reported previously, is a relatively large province in the high, rolling plain countryside of Central Anatolia in Turkey with a geographical surface area of 14123 km 2 . The province has 15 districts, 51 sub-districts and 556 villages. The estimated population is approximately 732127 based on the 2008 census, and 46% of this population live in urban areas, while 54% live in rural areas; 78% of the population of Yozgat works in the agriculture sector. The province, being 1300 m above sea level, has a typical semi-arid climate, with rainfall in winter and spring.
F. tularensis strains
Thirty-nine F. tularensis strains isolated from lymph node aspirate (n ¼20), throat smears (n¼17) and conjunctival swabs (n¼2) were used in this study. F. tularensis strains were isolated from patients residing in a total of 22 villages in 10 districts. Approximately half of the present collection (i.e. 19 isolates) were derived from patients living in eight villages and 9/19 were obtained from three separate villages in three different districts. Additionally, two strains were isolated from family members who contracted tularaemia by consumption of natural spring water. The live vaccine strain of F. tularensis type B (NCTC 10857) was used as a control strain.
Identification of F. tularensis strains
F. tularensis strains were identified using standard criteria as described previously. 6 Briefly, preliminary identification of typical colonies on glucose/cysteine blood agar (GCBA; brain heart infusion agar supplemented with 1% glucose monohydrate, 0.1% L-cysteine and 9% chocolatized sheep blood) were evaluated by Gram's stain, biochemical characteristics (oxidase, catalase, fermentation of glycerol and glucose), slide agglutination with F. tularensis antiserum (BD Bioscience, USA) and direct fluorescent antibody (DFA) staining with fluorescein isothiocyanate-conjugated anti-Francisella serum (BulBio-NCIPD, Sofia, Bulgaria).
DNA was extracted from pure cultures of F. tularensis strains by using a commercial DNA extraction kit (QIAamp DNA extraction mini kit; Qiagen, Germany) according to the manufacturer's instructions. Two PCR assays targeting different gene regions of F. tularensis were used for confirmation of species and determination of subspecies. For confirmation, a PCR assay targeting a gene (tul4) sequence specific for the 17 kDa membrane protein of F. tularensis was carried out. 7 Subsp. holarctica was identified by PCR targeting the RD ('region of difference') gene locus. 8 
Antimicrobial susceptibility testing
MICs of 24 antimicrobial agents (Table 1) were determined by Etest on GCBA plates supplemented with 9% sheep blood as described by Tomaso et al. 6 b-Lactamase production was determined with cefinase discs (Becton Dickinson) according to the manufacturer's instructions. CLSI guidelines have established breakpoints in the case of F. tularensis susceptibility testing for tetracycline, doxycycline, streptomycin, gentamicin, chloramphenicol, ciprofloxacin and levofloxacin. 9 In the absence of specific breakpoint data for F. tularensis, MIC values were interpreted according to CLSI criteria for Enterobacteriaceae.
6,9
Results
All strains included in this study showed the absence of oxidase and urease activity, and were weakly catalase positive. All strains were positive for acid production from glucose and no strain produced acid from glycerol and sucrose. Based upon biochemical reactions and a combination of species-and subspecies-specific PCR assays, all strains were confirmed to be F. tularensis subsp. holarctica. Erythromycin resistance was observed in all isolates, which were therefore assigned to biovar II.
Antimicrobial susceptibility
The MIC distributions for subsp. holarctica strains investigated in this study and other reports from European countries are presented in Table 1 . Based on CLSI breakpoints, all isolates were susceptible to aminoglycosides (gentamicin, amikacin, tobramycin and streptomycin), fluoroquinolones (ciprofloxacin, levofloxacin and moxifloxacin), tetracyclines (tetracycline and tigecycline), chloramphenicol and rifampicin. According to the MIC 90 values, levofloxacin (0.012 mg/L) was found to be the most active agent, followed by ciprofloxacin (0.016 mg/L), moxifloxacin (0.032 mg/L), gentamicin (0.25 mg/L), tigecycline (0.25 mg/L), tobramycin (0.25 mg/L) and tetracycline (0.38 mg/L).
Interestingly, linezolid, which has a good activity against resistant Gram-positive organisms such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), showed good in vitro activity against all the isolates (MIC range 0.5-4 mg/L). All subsp. holarctica strains were completely resistant to penicillins (ampicillin, amoxicillin/clavulanate and piperacillin/tazobactam), cephalosporins (cefoperazone/sulbactam, ceftriaxone, ceftazidime, cefepime, cefpirome) with MICs .256 mg/L and imipenem with MICs .32 mg/L. Slow and weak b-lactamase activity with cefinase discs was observed in all subsp. holarctica strains. All strains were also resistant to the macrolides erythromycin, azithromycin and lincosamide (clindamycin) with MICs .256 mg/L (Table 1) .
Discussion
In our study we addressed issues currently still under discussion, such as the most suitable method for establishing antimicrobial susceptibilities of F. tularensis subsp. holarctica and the choice of optimal antimicrobial therapy based on data available from the literature and our results.
In vitro efficacy of antibiotics against F. tularensis has usually been based on the determination of MIC values by broth microdilution, agar dilution and Etest methods. 6,10 -15 Until 2006, the standard procedures for in vitro susceptibility testing had not been determined for F. tularensis. Currently methods for MIC determination with a microbroth dilution method using cation-adjusted Mueller -Hinton broth supplemented with 2% defined growth supplement are described by CLSI. The breakpoints used for interpretation as susceptible are as follows: tetracycline/ doxycycline, ≤4 mg/L; streptomycin, ≤8 mg/L; gentamicin, ≤4.0 mg/L; chloramphenicol, ≤8 mg/L; ciprofloxacin, ≤0.5 mg/L; and levofloxacin, ≤0.5 mg/L. 9 Although the broth microdilution method is considered a reference method for MIC determination, Valade et al. 15 failed to obtain reproducible results due to a temporary inhibition of growth (regrowth phenomenon) for a number of antimicrobials except for gentamicin, ciprofloxacin and doxycycline. Additionally, most studies utilized the Etest method and usually declared concordant results. 6,13 -15 We therefore preferred the Etest method on the grounds of simplicity, less hands-on time, repeatability and reliability.
In the present study we determined in vitro susceptibilities to 24 antimicrobials, some of which have been commonly used in the treatment of tularaemia, by using Etest. The MIC values of streptomycin, gentamicin, tetracycline, ciprofloxacin, levofloxacin and chloramphenicol, interpreted according to the CLSI criteria, have shown ranges below the breakpoints for susceptibility determination (Table 1 ). Since the breakpoint MICs for susceptibility for other antibiotics are not yet established, MIC values were interpreted according to CLSI criteria for Enterobacteriaceae. According to these criteria, all isolates were resistant to b-lactams, cephalosporins and imipenem.
For decades, streptomycin and the tetracyclines were considered the treatment of choice for tularaemia. In the coming years, our results and the respective data currently reported in the literature will be critically appraised and the advantages/disadvantages and potential treatment options discussed.
Streptomycin was the first antibiotic utilized for the treatment of tularaemia and case series have documented its utility, with defervescence usually within 48 h of treatment and the fewest number of relapses. 1 -5 Although gentamicin may substitute for streptomycin, its toxicity, necessity for monitoring of serum levels and the necessity for parenteral administration preclude its wider use. 1 -4 Consistent with the results of previous studies, 6,10,11,13 -16 all isolates in this study were susceptible to streptomycin, gentamicin, amikacin and tobramycin. While streptomycin (MIC 90 1.5 mg/L) and amikacin (MIC 90 1.0 mg/L) were the least active, gentamicin (MIC 90 0.25 mg/L) and tobramycin (MIC 90 0.25 mg/L) were the most active aminoglycosides.
Tetracycline and its congeners have several advantages over aminoglycosides, including ease of oral administration and lower toxicities. 1, 4, 5 In our study, tetracycline (MIC 90 0.38 mg/L) exhibited good in vitro activity against all the isolates and MICs have shown ranges below the breakpoint for susceptibility determination (≤4 mg/L). Tigecycline, a member of a new class of antimicrobials, the glycylcyclines, reaches high intracellular concentrations in tissue, macrophages and neutrophils, which makes this agent an interesting alternative for the treatment of intracellular pathogens. 17 In this study, tigecycline was more active than tetracycline against subsp. holarctica strains, according to MIC 50 (0.19 mg/L) and MIC 90 (0.25 mg/L) values (Table 1) . No data about tigecycline's activity against F. tularensis have previously been reported in the literature. The low MICs of this antibiotic indicate that it might have some potential in the treatment of F. tularensis.
Although chloramphenicol was shown to be efficacious against F. tularensis, it is considered unreliable for the routine treatment of tularaemia, except meningitis, because of a higher rate of relapses and serious toxicity. 1,4 -6 According to the CLSI criteria 9 (susceptible ≤8 mg/L), all of our isolates were susceptible to chloramphenicol (MICs 0.094-0.25 mg/L).
In our study, all subsp. holarctica strains were highly resistant to penicillins, cephalosporins and carbapenems. Similar results have been reported from Spain 16 and Finland. 13 F. tularensis subsp. holarctica live-vaccine strain (LVS) has been reported to be resistant to ampicillin and penicillin, but susceptible to thirdgeneration cephalosporins and several penicillin-class antibiotics, including carbenicillin, piperacillin, ticarcillin and mezlocillin. 18 This apparent inconsistency between LVS and clinical isolates may be attributable to the existence of two chromosomally encoded subsp. holarctica LVS b-lactamases: bla1 LVS and bla2 LVS . While bla1 LVS did not encode a functional b-lactamase, bla2 LVS encoded a functional b-lactamase that is capable of hydrolysing penicillin-class b-lactam antibiotics, but not thirdgeneration cephalosporins. The susceptibility of LVS to piperacillin/tazobactam and third-generation cephalosporins may be attributed to a lack of bla2 induction in LVS. Another possible explanation for F. tularensis resistance to cephalosporin antibiotics is likely due to changes in cell permeability and/or the induction of active efflux mechanisms. 18 Although type A strains have been reported to be susceptible to erythromycin, 11 all isolates studied here were completely resistant to erythromycin, azithromycin and clindamycin. Similar findings have been reported previously. 6,13 -16,19 Therefore macrolides cannot be used for treatment of tularaemia due to the endemicity of subsp. holarctica biovar II in Turkey.
In this study, rifampicin has shown good in vitro activity against all the strains tested (MIC 0.25-1.0 mg/L). Although rifampicin has some toxicities and the potential for rapid emergence of resistance in monotherapy, our results as well as previous reports 6,13 -15 indicate that rifampicin might be useful in conjunction with fluoroquinolones in severe cases of tularaemia.
Linezolid has good activity not only against virtually all important Gram-positive pathogens, but potent in vitro activity against Mycobacterium tuberculosis, Mycobacterium avium complex and Nocardia spp. as well. 20 The MIC values of linezolid range from 0.5 to 2 mg/L at levels below the breakpoint for resistance (,4 mg/L) according to the CLSI interpretive criteria for Grampositive pathogens and at similar MIC levels as mycobacteria. 20 Although there is a lack of clinical data, linezolid has some advantages, such as good intracellular penetration, oral administration and the fact that dose adjustment in renal failure is not necessary; its in vivo efficacy remains to be confirmed for tularaemia.
Fluoroquinolones represent candidate therapeutic alternatives in first-line therapy for tularaemia because of their bactericidal effects, their ability to be orally administered, their excellent in vitro activity and the fact that drug level monitoring is not necessary. 1, 4, 12, 21 In the present study, fluoroquinolones exhibited the highest activity against subsp. holarctica. Levofloxacin (MIC 90 0.012 mg/L) was more active than ciprofloxacin (MIC 90 0.016 mg/L) and moxifloxacin (MIC 90 0.032 mg/L). The traditional, preferred therapy for all forms of tularaemia is streptomycin and to a lesser extent gentamicin in Turkey, but drawbacks exist such as a side effect profile of vestibular toxicity and nephrotoxicity, both of which require close monitoring, and the necessity for parenteral administration which requires an adequate healthcare network for outpatient treatment. However, due to the typically undramatic oropharyngeal clinical picture caused by subsp. holarctica in Turkey, on the grounds of the present results of our in vitro studies as well as some earlier reports of high treatment efficacy, 16,18,19,21 -23 treatment with fluoroquinolones represents a practical choice for ambulatory treatment and probably for hospital treatment.
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In conclusion, classically recommended therapeutics for tularaemia showed favourable in vitro antibacterial activity profiles against recently isolated subsp. holarctica strains. On the basis of our results, and in light of the existing literature, lesstoxic antimicrobials and their combinations may offer therapeutic alternatives for the treatment of F. tularensis subsp. holarctica infection and current guidelines warrant revision.
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